A retrospective study found that the 0.19 mg fluocinolone acetonide implant improved visual acuity and reduced retinal thickness in patients with non-infectious posterior uveitis over a mean follow-up period of nearly 30 months.

The study, published in the Journal of Ophthalmic Inflammation and Infection, involved 18 eyes from 13 patients treated at 3 ophthalmology departments in the Middle East between 2018 and 2021.

Baseline patient characteristics, including best-corrected visual acuity, central retinal thickness, and intraocular pressure, were recorded at the time of FAc implant administration and at subsequent intervals up to 36 months. The mean follow-up duration was 29.7 plus or minus 14.6 months.

Best-corrected visual acuity improved from month 1 (P = 0.002) and continued up to month 36 (P = 0.024). Central retinal thickness decreased from month 1 (P = 0.008) and remained lower throughout the follow-up period (P = 0.003). Anterior chamber cells and vitritis scores improved by month 6 (P = 0.004 and P = 0.001, respectively). Mean intraocular pressure remained stable over the follow-up period (P = 0.205).

The findings indicated the FAc implant provided sustained improvements in both functional and anatomical outcomes in patients with non-infectious posterior uveitis.

The authors reported no conflicts of interest.